Upstream Launches With $200m To Buy, Develop Drugs For Immune-Mediated Diseases

Lead Drug Candidate Targets TSLP Receptor For Asthma, Other Indications

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Upstream Bio acquired Phase Ib-ready UPB-101 from Astellas, and its experienced team plans to buy additional drug candidates for the treatment of allergic and inflammatory diseases. 

Lung health vector illustration
Upstream is focused on immune-mediated diseases, including asthma • Source: Shutterstock

Upstream Bio has been actively developing its strategy of acquiring externally discovered drug candidates for immune-mediated diseases for some time, but the start-up officially launched on 2 June with $200m in series A venture capital. It also debuted with a slate of experienced biotechnology entrepreneurs and former pharmaceutical executives to advance the company’s initial development program into a Phase Ib clinical trial and continue the hunt for additional assets.

CEO Samantha Truex previously helmed Quench Bio, Inc., served as chief operating officer of Synlogic, Inc. and was...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.